Rucaparib camsylate (also known as UNII-41AX9SJ8KO, 41AX9SJ8KO, CO-338) is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which work in DNA repair process. It has been found to have anticancer activity in a number of cancers and has been approved for treatment of previously treated, BRCA-mutant ovarian cancer.
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
 K.E.Parrish, et al, Mol. Cancer Ther., 2015, 14(12), pp 2735-2743.
 Z.B.Jenner, et al, Future Oncol., 2016, 12(12), pp 1439-1456.